Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BLTE
stocks logo

BLTE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.502
+56.88%
--
--
-0.620
+37.78%
--
--
-0.573
+14.67%
Estimates Revision
The market is revising No Change the revenue expectations for Belite Bio, Inc (BLTE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 130.10%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-2.67%
In Past 3 Month
Stock Price
Go Up
up Image
+130.10%
In Past 3 Month
Wall Street analysts forecast BLTE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLTE is 113.75 USD with a low forecast of 85.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast BLTE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLTE is 113.75 USD with a low forecast of 85.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 151.270
sliders
Low
85.00
Averages
113.75
High
140.00
Current: 151.270
sliders
Low
85.00
Averages
113.75
High
140.00
Maxim
NULL -> Buy
maintain
$140 -> $200
2025-12-02
New
Reason
Maxim
Price Target
$140 -> $200
2025-12-02
New
maintain
NULL -> Buy
Reason
Maxim raised the firm's price target on Belite Bio to $200 from $140 and keeps a Buy rating on the shares after the company reported positive topline results from the Phase 3 DRAGON trial of tinlarebant in adolescent Stargardt disease.
Mizuho
Graig Suvannavejh
Neutral -> Outperform
upgrade
$194
2025-12-02
New
Reason
Mizuho
Graig Suvannavejh
Price Target
$194
2025-12-02
New
upgrade
Neutral -> Outperform
Reason
Mizuho analyst Graig Suvannavejh upgraded Belite Bio to Outperform from Neutral with a $194 price target.
Mizuho
Graig Suvannavejh
Neutral -> Outperform
upgrade
$105 -> $194
2025-12-02
New
Reason
Mizuho
Graig Suvannavejh
Price Target
$105 -> $194
2025-12-02
New
upgrade
Neutral -> Outperform
Reason
Mizuho analyst Graig Suvannavejh upgraded Belite Bio to Outperform from Neutral with a price target of $194, up from $105. The firm cites the positive Phase 3 data for tinlarebant in Stargardt disease for the upgrade. The data are "impressive" and better than Mizuho's expectations on both efficacy and safety, the analyst tells investors in a research note. The firm increased its probability of success assumptions for tinlarebant to 85% from 40%-60% prior. Mizuho sees the drug's U.S. launch pricing at $350,000 and moved up its risk-unadjusted tinlarebant sales estimate to $4.2B. It sees further upside in the shares post the data.
Cantor Fitzgerald
NULL -> Overweight
initiated
$154
2025-11-24
Reason
Cantor Fitzgerald
Price Target
$154
2025-11-24
initiated
NULL -> Overweight
Reason
Cantor Fitzgerald assumed coverage of Belite Bio with an Overweight rating and $154 price target. Belite is set to report Phase 3 data this quarter for tinlarebant in Stargardt disease, with the readout notable because the one-year futility analysis already achieved statistical significance, the FDA granted breakthrough designation based on that interim success, and multiple regulators, including in China and the U.K., have agreed to accept filings using the interim data, the analyst tells investors in a research note.
Mizuho
Neutral
initiated
$105
2025-11-20
Reason
Mizuho
Price Target
$105
2025-11-20
initiated
Neutral
Reason
Mizuho initiated coverage of Belite Bio with a Neutral rating and $105 price target. The firm views Belite as a "unique, one-product story," with tinlarebant in Phase 3 for Stargardt disease. While the firm project $4B in peak worldwide sales for tinlarebant, it finds handicapping the Phase 3 outcome challenging. Tinlarebant's existing data on efficacy, "while promising," are not "particularly robust," the analyst tells investors in a research note.
Bruce Jackson
Buy
maintain
$80 -> $132
2025-10-31
Reason
Bruce Jackson
Price Target
$80 -> $132
2025-10-31
maintain
Buy
Reason
Benchmark analyst Bruce Jackson raised the firm's price target on Belite Bio to $132 from $80 and keeps a Buy rating on the shares. Belite is "approaching a series of major catalysts," beginning with the release of topline results during Q4 from the Phase 3 DRAGON study of Tinlarebant in Stargardts Disease, the analyst tells investors. The results, which are likely to be positive in the firm's view, combined with orphan drug designation, could result in attractive pricing, leading the firm to increase its pricing assumptions for the drug.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Belite Bio Inc (BLTE.O) is -65.86, compared to its 5-year average forward P/E of -35.09. For a more detailed relative valuation and DCF analysis to assess Belite Bio Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-35.09
Current PE
-65.86
Overvalued PE
-24.69
Undervalued PE
-45.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.62
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
15.40
Undervalued EV/EBITDA
-22.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.80
Current PS
0.00
Overvalued PS
55.75
Undervalued PS
-34.15
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

BLTE News & Events

Events Timeline

(ET)
2025-12-02
06:30:00
Morgan Stanley and Others Jointly Manage Offering Ranging from $150.00 to $154.00
select
2025-12-01 (ET)
2025-12-01
17:20:00
Morgan Stanley and Three Others Jointly Manage Offering
select
2025-12-01
16:30:00
Belite Bio Launches Underwritten Public Offering of ADSs
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-02Newsfilter
Belite Bio Prices 2.27M ADS Offering at $154 Each, Raising $350M
  • Significant Fundraising: Belite Bio successfully priced an offering of 2.27 million ADSs at $154 each, raising approximately $350 million, which will provide robust financial support for the company's future commercialization and R&D efforts.
  • Commercialization Preparation: The proceeds will be used to build an in-house commercialization team and sales network, ensuring a swift market entry for future products upon approval, thereby enhancing the company's competitive position in the ophthalmic drug sector.
  • Advancement of Clinical Development: Belite Bio plans to utilize part of the funds to expand its drug development pipeline, particularly targeting therapeutics for degenerative retinal diseases, further solidifying its leadership in this field.
  • Strong Underwriting Team: With prominent financial institutions like Morgan Stanley and BofA Securities acting as underwriters, the offering boosts market confidence in Belite Bio and lays a solid foundation for future capital operations.
[object Object]
Preview
8.5
12-02SeekingAlpha
Belite Bio sets price for 2.27 million ADSs at $154.00, aiming to raise $350 million in public offering

  • Public Offering Announcement: Belite Bio (BLTE) has priced an underwritten public offering of American Depositary Shares (ADSs) to raise approximately $350 million, with each ADS priced at $154.00.

  • Use of Proceeds: The company plans to allocate the net proceeds to build an in-house commercialization team, establish sales networks, support therapeutic pipeline development, and cover general corporate expenses.

  • Underwriter Option: Belite Bio has granted underwriters a 30-day option to purchase up to 340,909 additional ADSs at the same public offering price.

  • Closing Date: The closing of the offering is expected to occur on or about December 3, 2025.

[object Object]
Preview
4.0
12-02Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Belite Bio, Increases Price Target to $185

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Belite Bio Inc (BLTE) stock price today?

The current price of BLTE is 151.27 USD — it has decreased -0.34 % in the last trading day.

arrow icon

What is Belite Bio Inc (BLTE)'s business?

Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.

arrow icon

What is the price predicton of BLTE Stock?

Wall Street analysts forecast BLTE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLTE is 113.75 USD with a low forecast of 85.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Belite Bio Inc (BLTE)'s revenue for the last quarter?

Belite Bio Inc revenue for the last quarter amounts to -9.74M USD, decreased -0.00 % YoY.

arrow icon

What is Belite Bio Inc (BLTE)'s earnings per share (EPS) for the last quarter?

Belite Bio Inc. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Belite Bio Inc (BLTE)'s fundamentals?

The market is revising No Change the revenue expectations for Belite Bio, Inc (BLTE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 130.10%.
arrow icon

How many employees does Belite Bio Inc (BLTE). have?

Belite Bio Inc (BLTE) has 25 emplpoyees as of December 05 2025.

arrow icon

What is Belite Bio Inc (BLTE) market cap?

Today BLTE has the market capitalization of 5.33B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free